Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics announced that the FDA has granted priority review to the Biologics License Application for atacicept, targeting accelerated approval for treatment of IgA Nephropathy with a PDUFA date set for July 7, 2026. The company is progressing preparations for a U.S. commercial launch pending approval, strengthened its executive team, and r…